Prostate cancer trials in Czechia

In Czechia 17 Also abroad 1481

17 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Not yet taking people in Czechia
A clinical trial to learn more about the effects of AAA817 given with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
Where
Hradec Králové, Olomouc, Prague
Age
18 years and over
People
47 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-512340-32-01 · EU 2024-512340-32-01
Phase 2Taking people
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Where
Olomouc, Prague
Age
18 years and over
People
430 worldwide
Run by
Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00
Phase 3Taking people
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Where
Brno-Stred, Olomouc, Poruba, Prague
Age
18 years and over
People
1,310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00
No phaseTaking people
Cancer Survivors Program
Where
Brno
Age
18 years and over
People
200
Run by
Masaryk Memorial Cancer Institute
See details and how to joinNCT07253987
Phase 3Taking people
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Where
Liberec I-Stare Mesto, Olomouc, Ostrava, Pardubice, Prague, Prague 4
Age
18 years and over
People
900 worldwide
Run by
Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00
Phase 3Taking people
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Where
Brno-Stred, Olomouc, Ostrava, Prague
Age
18 years and over
People
1,440 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00
Phase 1/2Taking people
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Where
Olomouc
Age
18 years and over
People
205 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07288359
Phase 3Taking people
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Where
Olomouc, Poruba, Prague 5
Age
18 years to 100 years
People
450 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00
Phase 3Taking people
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Where
Brno-Stred, Olomouc, Prague, Prague 2
Age
18 years and over
People
1,314 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00
Phase 3Taking people
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Where
Brno-Stred, Hradec Králové, Nový Jičín, Olomouc, Prague
Age
18 years and over
People
1,000 worldwide
Run by
Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00
Phase 3Not yet taking people in Czechia
A clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of prostate cancer
Where
Brno-Stred, Olomouc, Prague 5
Age
18 years and over
People
63 worldwide
Run by
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
See details and how to joinNCT03520478 · EU 2024-515194-10-00
No phaseTaking people
The Effectiveness of Telemedicine Monitoring Prehabilitation in Prostate Cancer Patients Undergoing Radical Prostatectomy
Where
Olomouc
Age
40 years to 80 years
People
200
Run by
University Hospital Olomouc
See details and how to joinNCT06981026
Phase 4Taking people
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Where
Olomouc, Prague 5
Age
18 years to 100 years
People
700 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05803941 · EU 2023-503208-94-00
Phase 3Taking people
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
Where
Olomouc
Age
18 years and over
People
1,210 worldwide
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT03819101 · EU 2023-508072-11-00
Phase 3Taking people
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Where
Olomouc, Prague
Age
18 years and over
People
300 worldwide
Run by
UNICANCER
See details and how to joinNCT04916613 · EU 2022-502425-18-00
Phase 3Taking people
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
Where
Brno, Olomouc
Age
18 years to 100 years
People
1,600 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT05974774 · EU 2023-506817-23-01
No phaseTaking people
Stereotactic Radiotherapy of Prostate Cancer With Reduction of Safety Margins
Where
Ostrava
Age
18 years and over
People
100
Run by
University Hospital Ostrava
See details and how to joinNCT06665932